

PHARMING

HOME MEMBER STATE DECLARATION PURSUANT TO THE AMENDED ARTICLE 5:25A PARAGRAPH 2 OF THE DUTCH FINANCIAL SUPERVISION ACT

Leiden, The Netherlands, 26 February 2016: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM) notes that on 29 January 2016, the Amended Transparency Directive Implementation Act (Implementatiewet wijziging richtlijn transparantie) and the Amended Transparency Directive Implementation Decree (Implementatiebesluit wijziging richtlijn transparantie) entered into force. Pharming is incorporated in the European Union, in Leiden, the Netherlands and is listed on Euronext Amsterdam. As a result, Pharming hereby declares that the Netherlands is its “Home Member State” pursuant to the amended article 5:25a paragraph 2 of the Dutch Financial Supervision Act.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in the USA, Israel, South Korea, all 28 EU countries plus Norway, Iceland, and Liechtenstein.

RUCONEST is commercialized by Pharming in Austria, Germany and The Netherlands.

RUCONEST is distributed by Swedish Orphan Biovitrum AB (publ) (SS: SOBI) in the other EU countries, and in Azerbaijan, Belarus, Georgia, Iceland, Kazakhstan, Liechtenstein, Norway, Russia, Serbia, and Ukraine.

RUCONEST is distributed in Argentina, Colombia, Costa Rica, the Dominican Republic, Panama and Venezuela, by Cytobioteck.

RUCONEST is distributed in South Korea by HyupJin Corporation.

RUCONEST is partnered with Salix Pharmaceuticals, Ltd. (“Salix”) in North America. Valeant Pharmaceuticals International, Inc. (NYSE: VRX/TSX: VRX) completed its acquisition of Salix Pharmaceuticals, Ltd. on April 1, 2015.

RUCONEST is also being investigated in a randomized Phase II clinical trial for prophylaxis of HAE, in a phase II clinical trial for the treatment of HAE in young children (2-13 years of age) and evaluated for various additional follow-on indications.

Pharming has a unique GMP compliant, validated platform for the production of recombinant human proteins that has proven capable of producing industrial volumes of high quality recombinant human protein in a more economical way compared to current cell-based technologies. Leads for Enzyme Replacement Therapy (ERT) in Pompe, Fabry’s and Gaucher’s diseases are under early evaluation. The platform is partnered with Shanghai Institute of Pharmaceutical Industry (SIPI), a Sinopharm Company, for joint global development of new products. Pre-clinical development and manufacturing will take place at SIPI and are funded by SIPI. Pharming and SIPI initially plan to utilise this platform for the development of recombinant human Factor VIII for the treatment of Haemophilia A.

For more information, please visit <http://www.pharming.com>

Pharming Group

Sijmen de Vries, Chief Executive Officer

Tel: +31 71 5247400

FTI Consulting (Pharming media relations)

Julia Phillips / Victoria Foster Mitchell

Tel: +44 203 727 1136